TriSalus Life Sciences Inc.
TLSI | NASDAQ
$4.93
-$0.05 (-1.00%)
Sep 22, 2026, 12:34 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -3.79 | -4.01 | -3.79 | -6.31 | -10.74 | -461.40 |
PEG Ratio | -0.08 | 0.09 | -0.09 | -0.09 | 0 | n/a |
PS Ratio | 7.60 | 4.51 | 12.08 | 23.95 | 36.75 | n/a |
PB Ratio | -10.14 | -5.13 | -8.26 | -24.10 | 9.99 | -6.41 |
P/FCF Ratio | -18.14 | -3.22 | -4.37 | -8.97 | -12.89 | -474.47 |
P/OCF Ratio | -19.06 | -3.25 | -4.42 | -9.19 | -13.60 | -474.47 |
OCF/S Ratio | -39.89 | -138.78 | -273.23 | -260.63 | -270.17 | n/a |
Debt / Equity Ratio | -1.02 | -0.91 | -0.06 | -0.16 | n/a | -0.84 |
Quick Ratio | 2.54 | 1.63 | 1.25 | 0.49 | 5.31 | 0.10 |
Current Ratio | 2.80 | 2.02 | 1.42 | 0.53 | 5.51 | 0.11 |
Asset Turnover | 1.28 | 1.23 | 0.75 | 0.56 | 0.22 | n/a |
Interest Coverage | -4.86 | -11.70 | -3.4K | -36.44K | -13.65 | n/a |
Return on Equity | 115.85% | 128.34% | 219.33% | 382.89% | -93.34% | 63.46% |
Return on Assets | -111.03% | -138.64% | -241.33% | -214.54% | -76.23% | -391.61% |
Return on Invested Capital | -112.28% | -259.08% | -530.84% | 364.68% | -76.38% | 2.45% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 84.57% | 86.06% | 85.93% | 81.79% | 85.80% | n/a |
Net Profit Margin | -86.88% | -112.92% | -320.69% | -380.60% | -343.35% | n/a |
Pretax Profit Margin | -86.86% | -102.07% | -320.64% | -380.53% | -343.32% | n/a |
Operating Profit Margin | -59.68% | -122.88% | -294.28% | -293.91% | -286.06% | n/a |
FCF Margin | -41.93% | -139.95% | -276.41% | -266.97% | -285.14% | n/a |
EBITDA Margin | -73.20% | -110.04% | -316.86% | -377.18% | -316.83% | n/a |
Add to Watchlist
Select watchlists to add or remove TLSI